BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) has released its latest long-term safety and efficacy data from the trials studying once-daily, oral ORLADEYO (berotralstat) for prophylactic hereditary angioedema (HAE) treatment. The studies include findings demonstrating sustained HAE attack rates reduction and patient satisfaction improvement after patients change from injectable prophylactic therapies to ORLADEYO monotherapy.
The company presented the data from the studies at the 2021 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting conducted in New Orleans, Lousiana, on November 4 to 8, 2021.
Data presented supports ORLADEYO as an HAE therapy
BioCryst chief medical officer William Sheridan said, “We continue to see improvement in key indicators that demonstrate the value of oral, once-daily ORLADEYO as an excellent option for patients who want alternatives to injectable prophylactic therapies, which carry a high treatment burden. The data we are presenting at ACAAI further support ORLADEYO as a transformative therapy for HAE patients, including those who are already well-controlled on other therapies.”
University of California San Diego US HAEA Angioedema Centre Clinical Director Marc Riedl said, “The data from APeX-S showed that HAE patients who switched to ORLADEYO from an injectable prophylactic therapy had more than 80 percent attack free months. These data show that, regardless of which therapy patients switched from, or when they switched, ORLADEYO provided consistently low attack rates when used as a monotherapy. These important findings add to real-world evidence that this oral, once-daily therapy is a beneficial treatment option for many HAE patients.”
HAE Patients need a convenient treatment alternative
Jonathan Bernstein, Bernstein Allergy Group and Bernstein Clinical Research Center partner, said, “Increased satisfaction and improvement in quality of life continue to be major driving factors for patients who decide to switch to an oral prophylactic option, as shown in our analysis of patients who switched from injectable prophylaxis to ORLADEYO in APeX-2. These results underscore what I see every day in clinical practice, that HAE patients want a more convenient treatment option to control their HAE attacks and reduce their overall burden of therapy.”
